• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人肝细胞癌中p53免疫组化染色与突变的相关性

Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.

作者信息

Hsia C C, Nakashima Y, Thorgeirsson S S, Harris C C, Minemura M, Momosaki S, Wang N J, Tabor E

机构信息

Division of Transfusion Transmitted Diseases, Food and Drug Administration, Bethesda, MD, USA.

出版信息

Oncol Rep. 2000 Mar-Apr;7(2):353-6.

PMID:10671685
Abstract

Mutations of the p53 tumor suppressor gene are common in hepatocellular carcinomas (HCCs). Detection of mutations by sequencing provides more information than immunohistochemical staining, but the equipment needed and the time required make it less practical for use in large-scale studies or in studies in developing countries. The degree of correlation between results obtained with these two methods has been studied in various tumors but has not been well-established in human HCCs. Paraffin sections of HCCs of 28 patients from Qidong, China were immunohistochemically stained using monoclonal antibody to p53. In addition, exons 5-8 of the p53 gene were sequenced in these HCCs. Of the 28 HCCs, nine had 0-9% of nuclei stained for p53, and 19 had 50-95% stained. Mutations in p53 exons 5-8 were found in 17/28 (61%) HCCs, including 15 at codon 249 (exon 7), one at codon 198 (exon 6), and one at codon 175 (exon 5). Among these 17 cases with p53 mutations, 16 cases (94%) had 50-95% of nuclei stained. Among 11 HCCs with no mutations by sequencing, 8 were also negative by immunohistochemistry (0-9% of nuclei stained) (73%) (the five HCCs with no staining whatsoever all had wild-type p53). Immunohistochemical staining to detect p53 mutations in human HCCs detected most mutations that were detected by sequencing (94% sensitivity, 73% specificity), and this method is therefore suitable when sequencing cannot be performed.

摘要

p53肿瘤抑制基因的突变在肝细胞癌(HCC)中很常见。通过测序检测突变比免疫组织化学染色提供的信息更多,但所需设备和时间使其在大规模研究或发展中国家的研究中不太实用。这两种方法所得结果之间的相关程度已在各种肿瘤中进行了研究,但在人类HCC中尚未得到充分证实。对来自中国启东的28例HCC患者的石蜡切片用p53单克隆抗体进行免疫组织化学染色。此外,对这些HCC中的p53基因外显子5 - 8进行测序。在28例HCC中,9例p53染色的细胞核比例为0 - 9%,19例为50 - 95%。在28例HCC中有17例(61%)在p53外显子5 - 8中发现突变,包括15例在密码子249(外显子7)、1例在密码子198(外显子6)和1例在密码子175(外显子5)。在这17例有p53突变的病例中,16例(94%)的细胞核染色比例为50 - 95%。在11例测序未发现突变的HCC中,8例免疫组织化学也为阴性(细胞核染色比例为0 - 9%)(73%)(5例完全无染色的HCC均具有野生型p53)。免疫组织化学染色检测人类HCC中的p53突变能检测到大多数通过测序发现的突变(敏感性为94%,特异性为73%),因此当无法进行测序时,该方法是适用的。

相似文献

1
Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.人肝细胞癌中p53免疫组化染色与突变的相关性
Oncol Rep. 2000 Mar-Apr;7(2):353-6.
2
High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.高水平的p53蛋白表达与肝细胞癌中的p53突变不相关。
J Viral Hepat. 2004 Nov;11(6):502-10. doi: 10.1111/j.1365-2893.2004.00541.x.
3
p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese.香港华人肝细胞癌中p53基因突变谱
Oncogene. 1994 Mar;9(3):985-90.
4
Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.干扰素调节因子-1在人肝细胞癌中的肿瘤抑制作用
Clin Cancer Res. 2001 May;7(5):1293-8.
5
p53 gene in hepatocellular carcinomas from Australia.
Cancer Detect Prev. 1994;18(2):123-30.
6
State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses.过去和目前感染嗜肝DNA病毒的地松鼠和土拨鼠肝细胞癌中p53基因的状态
Cancer Res. 1994 Oct 15;54(20):5430-7.
7
Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma.肝细胞癌临床特征与线粒体D环区DNA突变的相关性
J Gastroenterol. 2004 Nov;39(11):1063-8. doi: 10.1007/s00535-004-1445-3.
8
[Aberrations of tumor suppressor genes in hepatocellular carcinomas].肝细胞癌中肿瘤抑制基因的畸变
Hokkaido Igaku Zasshi. 1994 Sep;69(5):1252-60.
9
p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation.p53过表达在欧洲肝细胞癌中很常见,并且很大程度上独立于密码子249热点突变。
Oncogene. 1994 Jan;9(1):195-204.
10
Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China.中国肝细胞癌中肿瘤抑制基因的改变及等位基因缺失
Cancer Res. 1994 Jan 1;54(1):281-5.

引用本文的文献

1
Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer.重组人腺病毒 p53 与姜黄素联合治疗肝癌的效果
Exp Ther Med. 2020 Nov;20(5):18. doi: 10.3892/etm.2020.9145. Epub 2020 Aug 26.
2
Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.经肝动脉化疗栓塞和人腺病毒 5 型联合治疗的肝细胞癌患者的总生存时间延长和癌症特异性死亡率降低:竞争风险分析。
J Gastrointest Surg. 2018 Jun;22(6):989-997. doi: 10.1007/s11605-018-3703-3. Epub 2018 Feb 12.
3
p19Arf inhibits aggressive progression of H-ras-driven hepatocellular carcinoma.
p19Arf 抑制 H-ras 驱动的肝细胞癌的侵袭性进展。
Carcinogenesis. 2018 Mar 8;39(3):318-326. doi: 10.1093/carcin/bgx140.
4
Immunohistochemical Determination of p53 Protein Overexpression for Predicting p53 Gene Mutations in Hepatocellular Carcinoma: A Meta-Analysis.免疫组织化学检测p53蛋白过表达以预测肝细胞癌中p53基因突变:一项荟萃分析
PLoS One. 2016 Jul 18;11(7):e0159636. doi: 10.1371/journal.pone.0159636. eCollection 2016.
5
Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation.人类肝细胞癌中的基因缺失和扩增:与肝细胞生长调控的相关性。
Am J Pathol. 2012 Apr;180(4):1495-508. doi: 10.1016/j.ajpath.2011.12.021. Epub 2012 Feb 8.
6
p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up.p53 基因治疗联合经导管动脉化疗栓塞治疗 HCC:一年随访。
World J Gastroenterol. 2011 Apr 28;17(16):2143-9. doi: 10.3748/wjg.v17.i16.2143.
7
Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization.经导管动脉化疗栓塞联合p53基因治疗成功管理肝细胞癌术后复发
World J Gastroenterol. 2005 Jun 28;11(24):3803-5. doi: 10.3748/wjg.v11.i24.3803.
8
p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma.p53基因(重组人p53腺病毒注射液)联合栓塞术克服了复发性肝细胞癌。
Gut. 2005 Sep;54(9):1318-9. doi: 10.1136/gut.2005.069237. Epub 2005 May 5.